|
WSWS : News
& Analysis : North
America
Influenza nearing epidemic levels in the US
By Debra Watson
22 December 2003
Use
this version to print
| Send this
link by email | Email the
author
Influenza outbreaks continue to progress across the United
States with the disease widespread in 36 US states, up from 24
in early December. The Centers for Disease Control now characterize
the flu outbreak as a likely epidemic.
The official count for child flu deaths has more than doubled
from last week, from 20 to 42. With three months left in the flu
season, stocks of vaccine are already depleted. Parents in Western
states, where the flu season first took hold, are traveling hundreds
of miles in search of vaccine for their children. At least 11
children have already died in Colorado from respiratory complications
related to the flu, and some US schools have been forced to shut
down because so many students are sick.
The federal Department of Health and Human Services (HHS) has
begun distributing an additional 100,000 doses of vaccine to health
care providers in the US. An additional 375,000 are to be purchased
in Europe. Because the current process used to manufacture flu
vaccine includes a mandatory incubation period, none of the three
US companies that make vaccines can manufacture more doses in
time for this flu season.
HHS and the US Centers for Disease Control (CDC) knew vaccine
makers had cut the number of doses produced for the 2003-2004
to 83 million doses, down 12 million doses from the previous year,
doing nothing to ensure ample supplies in anticipation of heavy
demand. The half-million new doses distributed by HHS are a drop
in the bucket, and it is becoming increasing clear that there
will be little protection for the population at large if the outbreak
develops into a full-blown epidemic. The high-risk categories
the CDC normally recommends for vaccination includes an estimated
185 million people.
HHS has also announced plans to distribute another 150,000
childrens doses in January. This is little comfort for worried
parents in states across the US who are learning too late that
this years predominant flu strain seems to be hitting children
very hard. Children under eight who are getting their first vaccine
must take it in two doses spaced a month apart, putting further
strain on vaccine stocks.
For hundreds of thousands of US families, the traditional holiday
season is being overshadowed by influenza concerns. Instead of
scrambling for gifts, this year many parents are racing the clock
to find the last doses of vaccine. Some are being forced to fork
over $65 to $75 for a flu nasal spray for their children. Most
parents wont find that either as only 4 million doses of
FluMist were manufactured. It costs three to four times more than
the traditional flu shot, and most insurance companies do not
cover the expense.
The flu season hit in early October in the Western US. Last
week, 200 people lined up for flu shots at the Clark County, Nevada,
Health District. The state had ordered a record 29,000 doses but
received only 16,000. By Friday, December 12, the Las Vegas
ReviewJournal reported one area hospital was seeing
two to three times more children than on a normal day, the
vast majority complaining of flu-like symptoms. Nevada State
epidemiologist Dr. Randall Todd said that 10 percent of patients
seen by doctors were complaining of influenza-like symptoms, up
from 6 percent reported during the peak of the flu season last
year.
The CDC reported deaths as a whole from influenza hovering
near epidemic levels. By early December at least 20 children had
died from encephalopathy and other complications of the flu. On
December 18, PBS News Hour reported that 40 percent of
7,800 influenza cases in Colorado were among children under five.
One doctor said cases of influenza were the highest she had seen
in 20 years.
Early warnings ignored
Despite a dramatic rise in the percentage of flu cases of the
more virulent type-A influenza over the past dozen years, the
government has done nothing to develop a coherent vaccination
plan for what should be a largely preventable disease.
Though an investigation of an unusual number of child deaths
in a Michigan influenza outbreak last winter is ongoing, the government
made no provision to ensure vaccination of the general population,
including healthy toddlers and schoolchildren. Normally, only
very young children have a death rate from influenza comparable
to that of the elderly. Up to this year, flu cases among people
over 65 resulted in 90 percent of all deaths from influenza in
any given year.
The CDC routinely recommends that adults over 50, children
6 months to 23 months, anyone with a chronic illness and anyone
who interacts with or cares for at-risk individuals get flu shot
every year. Pre-school and school-age children are not included,
although they are a prime vector for flu as their immune systems
are not fully developed. Because the disease spreads through droplets
from coughing or sneezing, congregation at nurseries and schools
increases the opportunity for the infection to spread. The past
few years have seen indications of increased influenza illness
and death among children under 21.
However, recommendation that a particular population get vaccinated
means little. Unacceptable levels of illness and large numbers
of preventable deaths each year are accepted by the authorities
as perfectly normal. The federal government takes no responsibility
for the serious public health task of protecting the population
from influenza epidemics. Every year, on average more than 100,000
people are hospitalized and 36,000 mostly elderly people die in
the US as a result of complications from the flu.
Disease prevention and treatment in the US are subordinated
to the profit drive of huge pharmaceutical companies, Wall Street
investors and business entrepreneurs, with the federal government
unwilling to allocate funding for basic vaccination programs.
Public health versus private profit
Despite the threat to public health posed by such a deadly
communicable disease, less than 10 percent of vaccine in any given
year is purchased by government entities. The patchwork of state,
county and other local health authorities organizing vaccination
campaigns is simply not designed to ensure full or even major
vaccination needs.
In America, the responsibility to pay for shots, and a doctor
or health care provider to administer them, falls completely on
the individual family. Even when programs are available at public
health clinics or at special vaccination venues in malls and supermarkets,
the over 40 million US citizens who have no health care coverage
must pay up to $20 for the shots.
For those with coverage, many basic health plans do not cover
such routine immunizations. Health Maintenance Organizations (HMOs)
do little to promote the annual flu shots. Though HMOs claim to
cover vaccines, a recent survey found that only a small percentage
of children insured by these plans actually got the vaccine.
Some health plans have agreed to pay for FluMist, but others
have no plans to pay the higher cost to protect children not vaccinated
before the shots ran out.
Pharmaceutical companies and vaccines
Complicating the picture is the questionable efficacy of the
vaccine formulation produced this year. One of the three components
of the vaccine may be at best only 40 percent effective in protecting
against the increasingly predominant Fujian-type virus. According
to CDC Director Dr. Julie Gerberding, the H3N2 Fujian strain is
turning up in three out of four cases cultured so far this year.
Thirty-five years ago there were 30 companies in the US producing
vaccine, but that number has dropped to only three. For some childhood
vaccines, there is only one supplier in the country. Several times
in recent years, this has led to shortages of vaccines, including
basic childhood vaccines.
This contraction in vaccine production was one of the factors
leading to the miscall on formulating this years vaccine.
Even though evidence from last years season argued for inclusion
of specific H3N2 Fujian protection when the new flu formula was
finalized in March, the decision was made to go with last years
formula, hoping the A/Panama component would offer some protection
against the newer strain. The CDC claimed the risk of changing
production would lead to delays or even the failure of at least
one of the private companies. They point out that only two companies
are still making the flu shot and there were serious manufacturing
delays in recent years.
Despite some hand-wringing by Democratic politicians, no one
is seriously suggesting the government take responsibility for
producing and distributing the vaccine. Such a program would run
counter to the free-market mantra of the Bush administration and
pose a threat to profits for the private health care industry.
Unlike expensive AIDS drugs, it is not the high cost, but rather
the low profit margin of vaccines that has reduced the number
of pharmaceutical companies willing to produce them. Since they
make only pennies on the dollar, they would rather shift their
efforts to marketing expensive designer drugs that yield high
profits. Many pharmaceutical companies have dropped out of flu
vaccine production altogether.
This year the pharmaceutical company Wyeth stopped production
of flu vaccine delivered by injection, and began marketing the
expensive nasal vaccine made by MedImmune. MedImmune spent $50
million for ad campaigns to doctors and the general public to
advertise its new vaccine, focusing on its painless delivery system.
Since the vaccine uses a live virus it is considered suitable
only for healthy individuals outside the CDCs high-risk
groups. Thus recipients of Medicare, the elderly and disabled,
who have been reimbursed for flu shot costs since 1993, cannot
be administered the nasal spray.
Chaos in the health care system
The Trust for Americas Health (TFAH) recently released
a report examining the allocation of $1.7 billion in federal funds
in 2002 and 2003 through the new Public Health Security and Bioterrorism
Preparedness Act. The TFAH report uncovered a deterioration of
public health entities in the US, despite federal funding, as
state after state faces near bankruptcy. They found 33 states
cut public health funds from 2002 to 2003. Six states, including
Michigan, Massachusetts, Montana, Alaska, Missouri and Oklahoma,
cut their budgets by more than 10 percent.
The report states, Only 13 states have a plan (complete
or draft form) for responding to the emergence of a flu outbreak,
which is viewed by health officials as potentially more devastating
than a bioterrorism attack. It calls influenza the
forgotten epidemic, and points to the Spanish flu that killed
30 million people worldwide in 1918, including over half a million
in the US.
According to the report, The CDC does not require each
state to submitted influenza strategy to the agency for analysis
and approval, and has yet to release a national plan for federal
response to pandemic flu. In fact, influenza is not even
a reportable disease, which means the CDC uses estimates based
on various sources to track its spread and mortality rate.
The report notes several examples of public health cutbacks
resulting from state budget crises. These include:
* In California, state public health laboratories could lose
from 16 to 20 percent of their state funding in fiscal year 2004
and the laboratory that serves the city of Oakland, as well as
contracts to do testing for other counties, may shut down completely.
* The Alabama Department of Public Health plans to lay off
250 people by the end of the year, close regional labs and curtail
its flu vaccination purchase and free flu shot program.
* In Larimar County in Colorado, one of the states hardest
hit in this years flu season, $100,000 in federal money
was added to the county health budget but $700,000 was eliminated
due to state cuts.
From epidemic to pandemic
The chaos surrounding the current US influenza outbreak underscores
the fact that the capitalist market system is unable to deal with
the complexities of a modern urban society. A health epidemic
in any country in the world could quickly spread to a world pandemic.
If health care workers in one of the most advanced capitalist
countries are prevented from effectively fighting even common
influenza by the vagaries of the market, what chances are there
for tackling more deadly emerging diseases?
The AIDS epidemic, recent outbreaks of West Nile virus, and
the SARS epidemic last March brought the international character
of infectious disease to the attention of millions. While US health
care workers come up against the dictates of the pharmaceutical
and health care profiteers, international collaboration by scientists
and clinicians is subordinated to the geopolitical interests of
individual nations. Medical workers are already pointing to an
unacceptable divide that leaves poor countries at a severe disadvantage
in accessing influenza vaccine.
See also:
Canada: Budget cuts played
pivotal role in SARS crisis
[24 May 2003]
The science and sociology
of SARS
Part 1: Viruses and the nature of present outbreak
[12 May 2003]
The science and sociology
of SARS
Part 2: Science, internationalism and the profit motive
[13 May 2003]
Top of page
The WSWS invites your comments.
Copyright 1998-2008
World Socialist Web Site
All rights reserved |